About This Report

PatentVest Pulse is the pathway-intelligence series from PatentVest, the integrated IP strategy, IP law, and IP portfolio management firm built around a proprietary research and data platform covering 150M+ patent publications, clinical pipeline data, and deal flow across every major therapeutic area.

Most IP reports tell you what has been filed. This one tells you what the filings mean. Where the thickets are forming, which estates are anchored to clinical assets versus sitting latent, where freedom-to-operate is about to get expensive, which players are assembling licensing-in positions, and which are quietly building a royalty claim against every molecule that reaches the market.

If you are running a triple-agonist program, evaluating one to license in, building a competitive follow-on, or deciding whether to spend $50M on a Paragraph IV challenge five years from now, the IP structure in this space is the single largest variable in your outcome. This report is the starting point. The work of mapping your specific position against the landscape documented below is what we do.

The Quick Version (For Anyone)

If you don't work in drug development, here is the whole story in two paragraphs.

Ozempic and Wegovy (semaglutide) are the first-generation obesity drugs. They work on one hormone receptor and produce about 15% weight loss. Mounjaro and Zepbound (tirzepatide) are the second generation. They work on two receptors and produce about 22%. The third generation, built around a single drug called retatrutide, works on three receptors and has just produced 28.7% weight loss in a Phase 3 trial, which is the range that bariatric surgery produces. For the first time in history, a once-weekly shot is matching what surgeons get with an operating room. The commercial question is no longer whether this is possible. It is who owns the technology, who reaches the market when, and whether real-world patients on real-world budgets with real-world side effects actually keep taking the drug long enough to hit the trial numbers.

Twenty-seven of these "triple agonists" are in development globally. Lilly's retatrutide is the clear lead. Novo Nordisk has spent over $4 billion building a four-program portfolio to catch up. Fifteen of the twenty-seven programs come out of China. One Korean company, Hanmi, has the only small-molecule version in the clinic. Pfizer just bought its way in through the acquisition of Metsera. Behind all of this, there is a patent landscape more valuable than the drugs themselves: whoever controls the composition, dosing, formulation, and method-of-use claims around this receptor combination controls a decade of revenue across what is likely to become the largest drug category in history. Sanofi has the largest patent position in the field and no disclosed clinical program, which means either an undisclosed asset or a very deliberate royalty strategy. This report maps every piece of that picture.

The Ten Things Worth Knowing

1. Retatrutide just broke the 28% ceiling. Lilly's triple agonist delivered a mean 28.7% body weight reduction at 68 weeks on the 12 mg dose in TRIUMPH-4 - roughly 71 pounds for the average enrollee. That is the first non-surgical intervention to match the low end of bariatric outcomes (~25-35% total body weight loss), and it happened in a population with obesity and knee osteoarthritis, the exact patient who until 2026 had no good option. The trial also flagged a new dose-dependent safety signal - dysesthesia, an abnormal nerve sensation such as tingling or burning - at 20.9% on the 12 mg arm, which will shape the label and the real-world dose pattern.
2. Semaglutide and tirzepatide are no longer the ceiling. Weekly semaglutide tops out near 15% placebo-adjusted. Tirzepatide tops out near 22%. Retatrutide's 12 mg arm added roughly six percentage points on top of tirzepatide - the same delta tirzepatide added on top of semaglutide. The incretin curve has another floor beneath it.
3. The glucagon receptor was presumed dead for a decade. From 1995 to 2015, every major pharma ran GCGR antagonist programs to lower glucose in diabetes. Merck's MK-0893, Lilly's LY2409021, and Pfizer's PF-06291874 all reached Phase 2 and all failed - transaminase elevations, LDL increases, weight gain. The pathway was written off as toxic. Retatrutide's headline finding is that glucagon agonism, co-tuned against GLP-1 and GIP, does the opposite: it burns fat through hepatic and thermogenic effects while the incretins suppress appetite and protect beta cells. The same receptor that killed a decade of programs is now the engine of the most potent obesity drug ever tested.
4. Twenty-seven triple agonists are in development. One in Phase 3, six in Phase 2, four in Phase 1, one at IND, fifteen preclinical. Fifteen of the twenty-seven originate in China - a higher share than any previous metabolic pathway. The U.S. fields Lilly, Novo (via the UBT-251 license and an internal NNC program), D&D Pharmatech (DD-03 / DD-15, both linked to Metsera and therefore now Pfizer after the 2025 acquisition), Protagonist, Cascade, and Rani. Korea has Hanmi. Every other serious program is Chinese.
5. Hanmi is the dark horse. HM-15275 is the only small-molecule modulator in the clinical stages of the field - every other Phase 1/2/3 asset is a peptide, an Fc fusion, or an antibody-drug conjugate. Hanmi's FDA IND cleared September 2025, U.S. Phase 2 first patient dosed January 2026, and the Phase 1 readout showed up to ~10% weight loss in four weeks in individual patients on a long-acting PK profile. Hanmi's patent estate mirrors that asset - heavy on half-life-extension chemistry and formulation, explicit triple-agonist composition of matter, and a clinical candidate to anchor the claims.
6. Novo Nordisk is building four triple-agonist shots at once. The company has an internal once-weekly peptide (NNC-06620419, Phase 2 started October 2025), a ~$2B license on United Laboratories' UBT-251 (Phase 1b/2a running, 19.7% weight loss at 24 weeks in the Chinese Phase 2), a $2.2B collaboration with Septerna for small-molecule oral GPCR agonists including a triple, and a long-running in-house discovery pipeline. Lilly's Phase 3 lead is real, but Novo is hedging across four mechanism-and-modality combinations in a way Lilly is not.
7. The first oral triple agonist tablet enters the clinic in H2 2026. Ascletis nominated ASC37 as a development candidate in November 2025 - a single molecule delivered as both a once-daily oral tablet and a once-monthly subcutaneous injection. Preclinical non-human primate data claims 5× / 4× / 4× greater potency than retatrutide at GLP-1R / GIPR / GCGR. U.S. IND submissions for both forms are planned Q2 2026. Rani Therapeutics is advancing a triple-agonist peptide via the RaniPill ingestible-capsule platform. If either works, the patient-compliance story around obesity care changes entirely.
8. IBI-3012 is a bet that nobody else in this field is making. Innovent filed an IND in March 2025 for an antibody-drug-conjugate format triple agonist - a modality never before deployed against incretin receptors. It is the only ADC in the entire pipeline. If the format holds, it would enable tissue targeting (liver-selective glucagon action, for example) that a free peptide cannot achieve.
9. Sanofi is the largest latent IP holder with no disclosed clinical asset. The company holds 114 publications across 14 patent families that are directly relevant to GCGR/GIPR/GLP-1R tri-agonism, weighted almost entirely toward method-of-use claims. Sanofi has no triple agonist in its public pipeline. That gap is the largest asymmetry between patent position and product position in the entire field, and it is the cleanest signal in the data that either Sanofi is preparing an undisclosed program or intends to collect royalties from everyone else.
10. The receptor ratio is the game, not the molecule. Retatrutide, UBT-251, survodutide (dual GCGR/GLP-1), and mazdutide (dual GCGR/GLP-1) all activate at least two of the same three receptors. What separates them is the ratio. Different programs bias toward GIPR potency (metabolic tolerability), GCGR potency (thermogenesis, fat oxidation, hepatic effects), or GLP-1R potency (appetite). The next decade of obesity drug development is a tuning exercise, not a discovery exercise, and the IP positions that will matter most are the narrow molecular claims that lock in specific ratios.

1.0 Why This Pathway, Why Now

Obesity is the most over-subscribed therapeutic area in modern pharma. The market for GLP-1 receptor agonists alone crossed $50 billion in 2024. Semaglutide (Wegovy) and tirzepatide (Zepbound) between them serve fewer than 15% of the U.S. obesity population and are already treated, inside drug development organizations, as commodity ingredients against which everything else is benchmarked. The question driving every investment decision in this space since mid-2023 has not been whether incretins work, but how much further they can go.

The triple agonist pathway is the answer emerging from that question. By simultaneously activating the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR), a triple molecule takes the two established incretin effects - appetite suppression and insulin secretion - and adds a third metabolic lever that GLP-1-only and GLP-1/GIP dual molecules cannot reach: direct stimulation of hepatic glucose and lipid metabolism, increased energy expenditure, and enhanced thermogenesis. The result, in animal models and now in human Phase 2 and Phase 3 trials, is not an incremental 1-2 percentage point gain over tirzepatide. It is a step-change of five to eight percentage points in mean body-weight reduction that pushes the category into territory previously reserved for bariatric surgery.

That step-change is the subject of this report. The thesis we test across the following ten sections is simple: the triple agonist pathway is the platform on which obesity pharmacotherapy crosses the threshold from serious medicine to surgical substitute. The question for investors, operators, and IP strategists is no longer whether this happens; TRIUMPH-4 answered that in April 2026. The question is who owns what when it does. The sections that follow walk the science, the pipeline, the clinical readouts, the deal map, and the patent layer that sits underneath all of it.

A note on what went into this. Every drug program mentioned here was cross-checked against the global clinical trial databases, the public patent record, sponsor press releases, peer-reviewed journals, and the disclosed financial terms of every relevant deal. The pipeline picture covers twenty-seven programs across fifty clinical trials. The patent picture covers roughly three thousand filings against the three receptors that define this category. If a number appears in this report, it is traceable to a public source.

2.0 The Glucagon Paradox

Before Retatrutide, the glucagon receptor had a twenty-year reputation for killing drug programs. The arc from villain to engine is the single most interesting scientific story in metabolic disease in the last decade, and it is the reason the triple agonist pathway exists as a category.

In plain English. The body has three hormones that together control hunger, blood sugar, and how fast you burn fat. For twenty years, pharma tried to shut the fat-burning one (glucagon) off because it raised blood sugar in diabetes. That strategy failed in every major program. Around 2015 a small group of scientists flipped the thesis: instead of shutting glucagon off, turn it on at the same time as the other two. The result is a drug that makes you feel full, stabilizes your blood sugar, and speeds up your metabolism simultaneously. That is retatrutide. The same receptor that killed a decade of drug programs is now the reason the most potent obesity drug ever tested works.

2.1 The Antagonist Era (1995-2015): Why Every Major Pharma Tried to Shut Glucagon Off

The textbook physiology is unambiguous. Glucagon, secreted by pancreatic alpha cells, opposes insulin. It drives hepatic glucose production, increases gluconeogenesis, and raises blood sugar. In type 2 diabetes, glucagon is elevated and inappropriately suppressed by glucose, contributing to fasting hyperglycemia. A reasonable person reading that paragraph in 1998 would conclude that shutting glucagon off - blocking the receptor - would be a useful diabetes therapy.

That reasoning drove roughly two decades of antagonist development. Merck's MK-0893, a small-molecule GCGR antagonist, reached Phase 2b in type 2 diabetes and showed meaningful HbA1c reductions - alongside dose-dependent LDL cholesterol increases, transaminase elevations, and modest weight gain that together made the molecule untenable as a chronic medicine. Lilly's LY2409021 showed the same pattern: efficacious glucose lowering, unacceptable hepatic and lipid signals. Pfizer's PF-06291874 reached Phase 2 with a similar profile. Isis (now Ionis) ran antisense programs against glucagon receptor expression, also showing efficacy but accompanied by hepatic steatosis findings that aligned with the small-molecule class. By 2015, the received wisdom across large-pharma endocrinology was that GCGR antagonism was pharmacologically interesting but pharmacokinetically and pharmacodynamically incompatible with chronic administration.

What that wisdom missed - and what a small group of academic endocrinologists, most prominently Richard DiMarchi's group at Indiana University, had begun to argue aggressively through the early 2010s - was that glucagon's metabolic role is not just "raise glucose." It is a broader lever on hepatic lipid handling, mitochondrial uncoupling, brown-fat activation, and energy expenditure. Shut glucagon off and you do lower glucose, but you also shut off the body's principal counter-regulatory fat-burning signal. Patients on antagonists gained weight and developed fatty liver because glucagon was doing useful work that was being blocked.

The reframe that followed was radical. If glucagon agonism added to GLP-1 agonism could deliver the incretin's appetite suppression and glycemic control while simultaneously driving the thermogenic, hepatic, and energy-expenditure benefits the antagonist programs had been inadvertently shutting off, the combination might outperform either lever alone. The question became engineering: could you build a molecule that activated glucagon enough to capture the fat-oxidation benefit without activating it so much that you re-introduced the glycemic penalty?

2.2 The Dual Pivot (2015-2022): Proof of Concept

The first generation of co-agonists answered that question empirically. Cotadutide (MedImmune, later AstraZeneca), a GLP-1/glucagon dual, showed clinically meaningful weight loss and transaminase reduction in non-alcoholic steatohepatitis - the opposite of the hepatic signal seen with antagonists. Oxyntomodulin-derived peptides from Indiana University's academic program and its commercial translation through Zealand Pharma and Boehringer Ingelheim reinforced the pattern: tuned GCGR agonism, kept in balance against GLP-1R agonism, was benign for the liver and additive for weight loss. Survodutide, Boehringer Ingelheim's GLP-1/glucagon dual, reached Phase 3 with placebo-adjusted weight-loss and MASH-resolution data that validated the mechanism. Mazdutide (Innovent's IBI362, licensed from Lilly), another GLP-1/glucagon dual, read out ~18.5% weight loss on its 9 mg arm in GLORY-2 - on par with semaglutide's 2.4 mg weekly ceiling, in a population with a ceiling for semaglutide of roughly 15%.

The signal from the dual era was unambiguous. Glucagon, when co-agonized with GLP-1, was not the villain of the antagonist era. It was a complementary fat-burning lever that added efficacy without the tolerability cost.

2.3 The Triple Thesis (2022-Present): Why Add GIP?

The final move - adding GIPR agonism - was motivated by tirzepatide. Lilly's dual GLP-1/GIP agonist reached Phase 3 in 2019 and read out body-weight reductions of roughly 22% at the 15 mg dose in SURMOUNT-1, meaningfully above semaglutide's ~15%. The mechanistic interpretation, debated for two decades, was that GIPR agonism did two things: it contributed to appetite suppression and energy expenditure in addition to GLP-1R activation, and - separately - it appeared to improve tolerability by reducing GLP-1-mediated nausea and GI adverse events. Higher doses of tirzepatide were tolerable where equivalent doses of a pure GLP-1 agonist would not be.

If you accept the dual evidence that GLP-1/GCGR adds 3-6 percentage points of weight loss on top of GLP-1 alone, and you accept the tirzepatide evidence that GLP-1/GIPR adds 6-8 percentage points on top of GLP-1 alone, the arithmetic of a tri-agonist that captures both effects is intuitively additive. Retatrutide was the first molecule to test that hypothesis in humans. The Phase 2 obesity trial, reported in the New England Journal of Medicine in 2023, showed 24.2% mean weight loss on the 12 mg arm at 48 weeks - the first peer-reviewed obesity pharmacotherapy readout to cross the 20% line. The TRIUMPH-4 Phase 3 readout in April 2026 extended that to 28.7% at 68 weeks in a population with knee osteoarthritis - a patient group in whom weight loss produces disproportionate benefit on a secondary outcome (pain) the trial measured and reported as a 75.8% reduction on the WOMAC pain index.

The paradox, resolved: glucagon was never the villain. The villain was blocking it. Agonizing it, tuned against the two incretins, is what pushes the category past 25% weight loss into the surgical-substitute range.

3.0 The Twenty-Seven Programs

The field is bigger than most investors assume and more concentrated in two geographies (U.S./Korea and China) than any previous metabolic pathway. Below is the full pipeline as of April 2026, organized by development phase.

3.1 Phase 3 (1 program)

Retatrutide (Eli Lilly) is the only triple agonist in Phase 3 as of this report. Seven additional TRIUMPH-family readouts are expected through the remainder of 2026, including obesity-only (TRIUMPH-1), obesity + diabetes (TRIUMPH-2), obesity + cardiovascular risk (TRIUMPH-3), SELECT-M (obesity in MASH), SLEEP (obstructive sleep apnea), BACK PAIN, and a cardiovascular/renal outcomes readout. A U.S. NDA filing is widely expected Q4 2026.

3.2 Phase 2 (6 programs)

• HM-15275 (Hanmi) - small-molecule modulator, U.S. Phase 2 initiated January 2026 post-FDA IND clearance September 2025. Phase 1 readout reported up to 10% weight loss in individual patients at four weeks.
• UBT-251 (United Laboratories / Novo Nordisk) - peptide agonist. Chinese Phase 2 readout February 2026 showed up to 19.7% mean weight loss at 24 weeks on the 6 mg QW dose (n=205). Chinese Phase 3 planned. Novo Nordisk initiated a global Phase 1b/2a in ~330 patients; global topline expected 2027.
• MWN-109 (Shanghai Minwei) - peptide agonist, Phase 2 initiated August 2025 in non-diabetic overweight/obese patients (China). Phase 1b MAD study running concurrently.
• MWN-101 (Shanghai Minwei) - Fc-fusion protein, Phase 2 ongoing since March 2024. Long half-life architecture.
• ZX2021 (Jiangsu Zhongxin / Kanion) - Fc-fusion protein, Phase 2 initiated June 2025. No public efficacy readout.
• NNC-06620419 (Novo Nordisk) - once-weekly peptide, Novo's in-house triple agonist. Phase 1 initiated December 2024, Phase 2 (NCT07101783) initiated October 2025. Novo is explicitly diversifying its triple-agonist bet alongside the UBT-251 partnership.

3.3 Phase 1 (4 programs)

• DR10627 (Zhejiang Doer Biologics) - peptide, unusual MoA profile listed as "GCGR antagonist / GIPR agonist / GLP-1R agonist" in the registry - a mixed-agonist/antagonist architecture that, if accurate, is materially different from the rest of the field. Phase 1 running since June 2022 with no new public milestone.
• DYX116 (Jiangsu Deyuan) - peptide/chemical, Phase 1 initiated April 2025.
• HEC-007 (Sunshine Lake Pharma) - peptide, Phase 1 initiated August 2025.
• HRS-4729 (Jiangsu Hengrui / Kailera Therapeutics) - injectable peptide, Phase 1 initiated January 2025. Kailera (a 2024 U.S. spin-out built on Hengrui-licensed incretins) IPO'd in 2025. HRS-4729 is earlier-stage than Kailera's lead asset HRS9531 (dual GLP-1/GIP, positive Chinese Phase 3 February 2026, ~17.7% weight loss).

3.4 IND (1 program)

• IBI-3012 (Innovent Biologics) - antibody-drug conjugate format, the only ADC triple agonist in the pipeline. IND filed March 2025. The modality is novel enough that if Phase 1 PK/PD confirms durable receptor coverage, it will open an entirely new format vector for incretin drug development.

3.5 Preclinical (15 programs)

• ASC37 (Ascletis Pharma) - peptide in both oral tablet and once-monthly subcutaneous formulations. U.S. FDA IND for both forms planned Q2 2026; Phase 1 initiation H2 2026. Preclinical NHP data claims ~5× / 4× / 4× greater potency than retatrutide at GLP-1R / GIPR / GCGR, with ~1-month injection durability.
• DD-03 and DD-15 (D&D Pharmatech / Metsera → Pfizer) - recombinant polypeptide triple agonists licensed from D&D to Metsera; Metsera was acquired by Pfizer in 2025, which means Pfizer's publicly visible triple-agonist exposure is principally via these two preclinical assets.
• SP-2297 (Septerna / Novo Nordisk) - small-molecule oral GPCR triple agonist; one of four oral small-molecule programs under the May 2025 Septerna-Novo collaboration (up to $2.2B total deal value with $200M+ upfront).
• GLP-1 Incretin Triagonist (Rani Therapeutics) - peptide in the RaniPill ingestible-capsule oral delivery platform. Preclinical.

DR10627-family, XGLP/GCG/GIP-32 (Guangxi Medical University / Jiangsu Normal University), TRA24 (Henan University of Technology / Chia Tai Tianqing / Shanghai Duomirui), PB-2309 (PegBio), PN-477 (Protagonist Therapeutics), CS-14 and CS-120070 (Cascade Pharmaceuticals, peptide and small-molecule respectively), FD1016 (Suzhou Yihe), UTG-4 (Guangzhou University of Chinese Medicine), XFL6 (Xi'an Jiaotong First Affiliated Hospital), RAY-0221 (Raynovent, small molecule) - a long tail of Chinese preclinical programs, predominantly peptide-format, mostly targeting obesity with secondary positioning in type 2 diabetes and MASH.

3.6 Structure of the Pipeline

Counting by originator country: 15 of 27 are Chinese, 7 are U.S. (including Novo's NNC through its U.S. organization; Protagonist, Cascade, Rani are U.S. but two of those are academically linked), 1 is Korean (Hanmi), and 4 are partnerships that span geographies (Septerna-Novo, Hengrui-Kailera, D&D-Metsera-Pfizer, United Laboratories-Novo).

Counting by molecule type: 17 are peptides, 4 are small molecules (HM-15275, SP-2297, CS-120070, RAY-0221), 2 are Fc-fusion proteins (MWN-101, ZX2021), 1 is an ADC (IBI-3012), and 2 are listed as "chemical drugs" without more specificity (DYX116, XFL6).

Counting by indication: all 27 list obesity as an active indication. Twenty also list type 2 diabetes. Twelve also list metabolic dysfunction-associated steatohepatitis (MASH / MAFLD / MASLD).

Three features of this pipeline deserve explicit mention because they alter the strategic picture substantially:

1. Small-molecule oral triples are emerging. Three distinct programs (Hanmi's HM-15275, Septerna-Novo's SP-2297, Cascade's CS-120070) and one academic exploration (RAY-0221) are pursuing small-molecule agonists. A peptide triple must be injected or delivered through an engineered oral platform (Rani, ASC37's oral form). A true small-molecule oral triple, if it reaches efficacy parity, collapses the patient-compliance barrier that has limited GLP-1 penetration.
2. The Novo ecosystem is diversified. Novo is not one bet. It is four: UBT-251 (license), NNC-06620419 (internal peptide), SP-2297 (Septerna small-molecule), and ongoing in-house discovery. The cumulative commitment exceeds $4B in deal value.
3. The ADC format is a genuinely new vector. Innovent's IBI-3012 IND is the first incretin receptor asset to use an antibody-drug conjugate architecture. If the format is tractable, it could enable liver-selective glucagon agonism - a therapeutic window no peptide can achieve.

4.0 Asset Profiles

Individual drug profiles organized by phase, starting with the lead and working back. Each profile covers mechanism, molecule architecture, sponsor / ownership, clinical status, known efficacy and safety data, differentiation versus the class, and IP positioning.

4.1 Retatrutide (LY3437943) - Eli Lilly & Co.

What it is. Retatrutide is a synthetic 39-residue peptide triple agonist of the glucagon receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon-like peptide-1 receptor. The molecule is Lilly's in-house design, descended from a line of Indiana University academic work (the DiMarchi group) that Lilly has systematically productized through tirzepatide and now retatrutide. The peptide carries 2-aminoisobutyric acid substitutions at positions 2 and 20 to resist dipeptidyl peptidase-4 degradation, a C-terminal amide, an N6-substituted lysine C18-diacid fatty acyl side chain for albumin binding and half-life extension, and a 2-methyl leucine substitution for selectivity tuning. The half-life is approximately six days, supporting once-weekly subcutaneous dosing at target doses of 4, 8, and 12 mg. In plain terms: the molecule is engineered to shrug off the enzymes that would normally destroy it, to stick to a blood protein so it clears slowly, and to hit the three receptors in a specific ratio - which together allow a once-weekly injection at commercial dose strengths.

Receptor ratios. Retatrutide's in vitro cAMP potency is reported as roughly balanced across the three receptors with a bias toward GCGR and GIPR relative to GLP-1R. In the published Phase 1/2 data, the clinical signature is consistent with that pharmacology: strong appetite suppression (GLP-1R-mediated), preserved glycemic control and improved tolerability versus pure GLP-1 agonists at equivalent weight-loss doses (GIPR-mediated), and meaningful thermogenic/fat-oxidation contribution above and beyond dual GLP-1/GIP activity (GCGR-mediated).

Clinical status.

Phase 1 initiated March 2019.

Phase 2 obesity trial (NCT04881760) readout 2023 in NEJM: 24.2% mean weight loss on 12 mg at 48 weeks, n=62; 21.7% on 8 mg; 17.5% on 4 mg; 8.7% on 1 mg. The 12 mg arm was the first obesity pharmacotherapy readout to cross the 20% line.

Phase 3 TRIUMPH program initiated May 2023.

TRIUMPH-4 readout April 2026: 28.7% mean weight loss at 68 weeks on 12 mg in a population with obesity and knee osteoarthritis, approximately 71.2 lbs mean absolute loss. WOMAC pain index reduction of 75.8%. Dysesthesia signal flagged at 9 mg (8%) and 12 mg (20.9%) - a sensory nerve finding the label will almost certainly carry.

Seven additional Phase 3 readouts expected through 2026: TRIUMPH-1 (obesity), TRIUMPH-2 (obesity + diabetes), TRIUMPH-3 (obesity + cardiovascular risk), SELECT-M (MASH), SLEEP (OSA), BACK PAIN, and a cardiovascular/renal outcomes readout.

U.S. NDA filing expected Q4 2026.

Safety signal to watch. The dysesthesia finding is unusual in the incretin class. Retatrutide's GCGR agonism is the most likely pharmacological explanation - glucagon has documented effects on sensory and autonomic nervous system function - and the dose-dependence (absent at lower doses, material at 9 and 12 mg) supports that hypothesis. Whether this caps the commercial dose below 12 mg or becomes a labeled warning with chronic use resolution is the single most important open question for the asset.

IP position. Lilly's triple-agonist estate in the data set spans 25 publications across 6 patent families, heavily weighted toward explicit triple-agonist composition-of-matter claims, half-life extension chemistry, and formulation. Lilly also has two publications in the oral delivery bucket - the earliest hint that an oral retatrutide or a retatrutide successor may be in preclinical development. The original Indiana University filings that underpin the DiMarchi peptide chemistry remain a distinct estate (39 publications, 7 families) that Lilly has historically been the principal exclusive licensee of.

Differentiation. First to market. First to cross 25% placebo-adjusted weight loss. Broadest Phase 3 readout program. Only triple agonist with an on-label comorbidity finding (knee OA pain) and multiple cardiovascular and renal outcomes trials running. The differentiation Retatrutide does not have, and will not have, is convenience - it is a once-weekly injection, the same patient experience as semaglutide and tirzepatide.

4.2 HM-15275 - Hanmi Pharmaceutical

What it is. A small-molecule (modulator) triple agonist of GCGR, GIPR, and GLP-1R. Hanmi lists the MoA as "modulators" rather than "agonists," which in the company's usage typically connotes a small-molecule allosteric or biased-agonist architecture rather than a pure peptide orthosteric agonist. The molecule is intended for a long-acting PK profile - early disclosure suggests once-weekly dosing is plausible, potentially with a dosing frequency exceeding standard small-molecule administration.

Receptor ratios. Not publicly disclosed at sufficient resolution. Hanmi's public statements reference "favorable long-acting PK" and "potential best-in-class" positioning.

Clinical status.

First IND application February 2024 (Korea).

First Phase 1 May 2024.

FDA IND clearance September 2025.

U.S. Phase 2 first patient dosed January 2026.

ObesityWeek 2025 Phase 1 disclosure: approximately 5% mean weight loss at 4 weeks, with up to 10% in individual responders.

Differentiation. HM-15275 is the only small-molecule triple modulator in clinical development. If the Phase 2 readout confirms durable weight loss on par with peptide triples with a better tolerability profile and a dosing convenience advantage, HM-15275 becomes the most commercially interesting asset in the field after Retatrutide. The risk is that small-molecule agonism of Class B GPCRs (the incretin receptor family) is historically difficult - the natural ligands are peptides, and achieving both potency and selectivity in a small-molecule scaffold against three Class B GPCRs simultaneously is a significant medicinal-chemistry achievement in its own right.

IP position. Hanmi's estate is the largest in the field by publication count (107 publications, 17 patent families), heavily weighted toward explicit triple-agonist composition claims, half-life extension chemistry, and formulation. The estate is anchored on clinical assets rather than being hypothetical - HM-15211 (an earlier Hanmi triple agonist) and HM-15275 both sit inside the patent family structure, and the formulation and delivery filings support the asset's long-acting positioning. Hanmi is the only top-IP holder in the field with a clinical-stage triple agonist in its own pipeline.

4.3 UBT-251 - United Laboratories / Novo Nordisk

What it is. A synthetic peptide triple agonist developed by The United Bio-Technology (Hengqin) Co., a subsidiary of The United Laboratories International Holdings (a Hong Kong-listed Chinese pharmaceutical company). The molecule is dosed subcutaneously once weekly at target doses of 2, 4, and 6 mg.

Clinical status.

First IND application June 2023 (China).

First Phase 1 October 2023.

First Phase 2 March 2025.

Phase 2 obesity topline February 2026: up to 19.7% mean weight loss at 24 weeks, n=205 across 2 / 4 / 6 mg QW arms (China).

Phase 2 T2D topline March 2026: up to 2.16% HbA1c reduction at 24 weeks.

Chinese Phase 3 in obesity planned.

Novo Nordisk initiated global Phase 1b/2a in approximately 330 patients post-licensing deal; global topline expected 2027.

Novo Nordisk deal. Novo licensed UBT-251 from United Laboratories in 2024 in a transaction widely reported at approximately $2 billion total deal value. The license is a reaction to Lilly's Phase 3 lead with Retatrutide: Novo, which did not have an internal triple agonist in the clinic at the time, moved to acquire the fastest-advancing Chinese triple to compete on timeline with Retatrutide.

Differentiation. UBT-251's 19.7% at 24 weeks is the strongest weight-loss readout in the field outside of Retatrutide and within the shortest trial duration of any Phase 2 triple (most Phase 2 obesity trials run 36-48 weeks). If the linearized extrapolation holds, UBT-251 at 48 weeks could approach Retatrutide's Phase 2 24.2% number. The caveat is that the 24-week readout was in a Chinese population at Chinese sites; generalization to a global trial - the Novo Phase 1b/2a - is the critical bridge.

IP position. United Laboratories' publications are in the sub-set that, by title, Boolean match the triple-agonist keyword set and weight-adjacent language. The specific family structure is not well surfaced in the PV dataset - the PV assignee labels for United Laboratories are inconsistent. Novo's global filings against UBT-251 post-license are the relevant forward-looking IP event.

4.4 MWN-109 and MWN-101 - Shanghai Minwei Biotechnology

What they are. Two triple-agonist programs from Shanghai Minwei, run in parallel. MWN-109 is a synthetic peptide in Phase 2 since August 2025, with a concurrent Phase 1b MAD study. MWN-101 is an Fc-fusion protein in Phase 2 since March 2024 - notably, MWN-101's Fc architecture suggests a longer half-life than a standard fatty-acid-conjugated peptide, which would support less-frequent-than-weekly dosing.

Clinical status. Both in Phase 2 (China). No public efficacy readouts for either program as of April 2026.

Differentiation. Minwei is betting on two different molecule architectures (peptide, Fc-fusion) in parallel - a hedged position that no other single sponsor in the space is running. If either reads out competitively, it validates the sponsor as a credible platform developer.

4.5 ZX2021 - Jiangsu Zhongxin Pharmaceutical

What it is. Fc-fusion protein triple agonist, licensed between Jiangsu Zhongxin and Jiangsu Kanion Pharmaceutical. Phase 2 initiated June 2025. No public efficacy readout.

Differentiation. One of only two Fc-fusion triple agonists in Phase 2 (the other is MWN-101). The Fc-fusion architecture implies a dosing cadence longer than weekly, plausibly every-two-weeks or monthly, which differentiates on convenience if efficacy holds.

4.6 NNC-06620419 - Novo Nordisk

What it is. Novo Nordisk's internal once-weekly peptide triple agonist, distinct from UBT-251. Phase 1 initiated December 2024. Phase 2 (NCT07101783, multi-dose in overweight/obesity) initiated October 2025.

Differentiation. Novo's in-house bet. The fact that NNC-06620419 exists as a separate program from the $2B UBT-251 deal is the strongest single indicator that Novo views triple-agonism as a modality it intends to compete on across multiple parallel assets rather than through a single licensed molecule. The clinical timeline lags UBT-251 (the global Novo Phase 1b/2a of UBT-251 and NNC-06620419 Phase 2 are running in overlapping time frames), which is consistent with NNC-06620419 as a successor or differentiated backup rather than a replacement for UBT-251.

4.7 HRS-4729 - Jiangsu Hengrui / Kailera Therapeutics

What it is. Injectable triple-agonist peptide originated at Jiangsu Hengrui Pharmaceuticals (China's largest indigenous pharmaceutical company) and licensed to Kailera Therapeutics for ex-Greater-China rights. Kailera - a 2024 U.S. spin-out built around Hengrui-licensed incretin assets - IPO'd in 2025 with HRS-4729 as part of a portfolio anchored on HRS9531 (a dual GLP-1/GIP agonist that read out ~17.7% weight loss in Phase 3 in China in February 2026). HRS-4729 is the earlier-stage triple-agonist backup within that portfolio. Phase 1 initiated January 2025.

Differentiation. Positioning within the Kailera platform is as a next-generation asset behind HRS9531. If HRS-4729 advances through Phase 2 with efficacy superior to HRS9531, Kailera will face a portfolio-prioritization decision that meaningfully influences the pipeline structure.

4.8 DR10627 - Zhejiang Doer Biologics

What it is. The pipeline registry lists DR10627 with an unusual MoA: "GCGR antagonists / GIPR agonists / GLP-1R agonists" - a mixed agonist/antagonist architecture against the three receptors. If the registry is accurate, this is a materially different pharmacology than the rest of the field, and closer in spirit to a "balanced" metabolic-lever approach than a pure triple agonist. Phase 1 initiated June 2022 with no new public milestone as of April 2026, suggesting either quiet progression or clinical hold.

Differentiation. The only registry-labeled mixed-agonist/antagonist triple in the field. If the clinical profile is additive rather than conflicting, this becomes an interesting scientific data point - GCGR antagonism plus GIP/GLP-1 agonism recovers the diabetes-lowering benefit the antagonist era sought while preserving the incretin-driven appetite effect.

4.9 IBI-3012 - Innovent Biologics

What it is. An antibody-drug conjugate format triple agonist. IND filed March 2025. This is the only ADC in the entire pipeline and the first ADC architecture deployed against incretin receptors.

Why it matters. An ADC format provides three capabilities that a peptide agonist cannot: (1) antibody-mediated tissue targeting (for example, liver-selective glucagon agonism, which would decouple hepatic fat-burning effects from peripheral glucagon exposure); (2) substantially extended half-life via antibody FcRn recycling, enabling monthly or longer dosing; (3) payload-mediated receptor engagement with potential for novel agonist pharmacology (biased signaling, sustained activation) not achievable with a small peptide. The format risk is commensurately significant: ADCs are manufacturing-complex, immunogenicity-prone, and have never been validated against Class B GPCRs. Innovent is betting that the format's tissue-targeting advantage outweighs those risks.

Differentiation. Genuinely first-in-class modality within the triple agonist category. If IBI-3012 Phase 1 establishes durable tissue-biased receptor activation, the asset opens a modality vector nobody else in the field is positioned for.

4.10 ASC37 - Ascletis Pharma

What it is. A peptide triple agonist formulated both as a once-daily oral tablet and a once-monthly subcutaneous injection. Preclinical, with U.S. FDA IND submissions for both forms planned Q2 2026 and Phase 1 initiations H2 2026.

Preclinical claim. NHP data reports ~5× / 4× / 4× greater potency than Retatrutide at GLP-1R / GIPR / GCGR, with approximately one-month injection durability.

Why it matters. ASC37 is the only asset in the pipeline with a credible oral-tablet development plan that is not dependent on an engineered delivery device (as Rani's is). If the oral bioavailability data holds through Phase 1 human PK, ASC37 becomes the first oral triple agonist in the clinic - a meaningful patient-compliance story against injectable semaglutide, tirzepatide, and Retatrutide. The monthly subcutaneous form is simultaneously the longest-interval dosing in the field.

Risk. Oral peptide bioavailability is historically poor (oral semaglutide requires the SNAC absorption enhancer and still achieves single-digit % bioavailability). A tablet-formulated triple agonist peptide is mechanistically plausible but operationally difficult.

4.11 DD-03, DD-15 - D&D Pharmatech / Metsera / Pfizer

Both preclinical recombinant polypeptide triple agonists originated at D&D Pharmatech (Korean biotechnology company) and licensed to Metsera (a U.S. obesity-focused biotech). Metsera was acquired by Pfizer in 2025, which means Pfizer's principal visible triple-agonist exposure is via these two preclinical assets. Neither has a public clinical development timeline as of April 2026.

Why it matters. Pfizer is the fourth of the top global pharma obesity competitors (behind Lilly, Novo, and Boehringer). The company's acquisition of Metsera brought it into the triple agonist field at a preclinical stage, materially behind Lilly's Phase 3 lead and Novo's diversified $2B+ platform. If DD-03 or DD-15 progresses to IND in 2026-2027, it establishes Pfizer's seat at the table; if they remain preclinical, Pfizer's commercial obesity position faces a meaningful gap at the high-efficacy end of the category.

4.12 SP-2297 - Septerna / Novo Nordisk

What it is. A small-molecule oral triple agonist, one of four GPCR programs under the May 2025 Septerna-Novo Nordisk collaboration (up to $2.2B total deal value, $200M+ upfront). Preclinical.

Why it matters. This is Novo's small-molecule oral hedge against Ascletis's ASC37 and against the mechanistic possibility that the dominant obesity delivery vector over the next ten years shifts from injectable peptide to oral small molecule. Combined with Novo's existing peptide commitments (UBT-251, NNC-06620419), SP-2297 completes a four-program portfolio across modalities.

4.13 Rani Therapeutics Oral Triple Agonist

What it is. A preclinical triple-agonist peptide delivered via the RaniPill ingestible capsule platform, which uses an auto-injection mechanism inside the gastrointestinal tract to deliver peptide drugs with parenteral-like PK via oral administration. Preclinical.

Differentiation. The only triple agonist program to pair a peptide molecule with an engineered oral-delivery platform. The RaniPill platform itself has been clinically validated in other indications (Rani's GLP-1 RaniPill has been in human PK studies), but the triple-agonist program specifically is earlier-stage.

4.14 The Chinese Clinical and Preclinical Long Tail

Two early-clinical Chinese programs round out the Phase 1 picture: DYX116 (Jiangsu Deyuan Pharmaceutical, Phase 1 initiated April 2025) and HEC-007 (Sunshine Lake Pharma, Phase 1 initiated August 2025). Both are peptide programs with no public efficacy readouts; their existence is itself the data point, signalling the breadth of Chinese industry participation in the pathway.

Behind them sits the preclinical long tail - XGLP/GCG/GIP-32, TRA24, PB-2309, PN-477, CS-14, CS-120070, FD1016, UTG-4, XFL6, RAY-0221 - spanning synthetic peptides, small molecules, and academic discovery efforts across Chinese universities, state pharmaceutical institutes, and smaller private biopharma. Collectively they represent a depth of preclinical discovery activity in China that has no parallel in the U.S., Europe, or Korea. A plausible reading is that within the next three to five years, one to three of these programs will advance to IND, and one or more will be candidates for licensing by Novo, Lilly, Pfizer, Roche, or a mid-cap U.S. obesity-focused biotech. Cascade Pharmaceuticals (CS-14 peptide, CS-120070 small molecule) is the only U.S.-based sponsor running the two-molecule-format hedge at preclinical stage.

5.0 What Breaks Next (The Last 20% Thesis)

The central commercial question for the category is not whether Retatrutide gets approved - TRIUMPH-4's 28.7% at 68 weeks in a real-world comorbid population is unambiguous efficacy and will be approvable. The question is whether the category scales beyond the narrow population for whom the top-line number is observed under clinical-trial conditions. Four things break that scaling story, and the sequence in which they break determines which sponsors win.

5.1 The Real-World Ceiling Is Lower Than the Trial Ceiling

The bar against which Retatrutide will be measured commercially is not its own Phase 3 number. It is what semaglutide and tirzepatide have delivered in real-world clinical practice over 2024 and 2025 - and that gap is instructive. In Cleveland Clinic's 2025 analysis of real-world use, semaglutide 2.4 mg produced mean weight loss of approximately 14.1% at one year versus the ~15% trial number, and tirzepatide produced approximately 16.5% versus the 22% trial number. Tirzepatide's gap is particularly revealing: the drug loses roughly one-quarter of its trial-observed efficacy on the way to the real-world population. The mechanical causes are well understood - patients titrate more slowly, reach lower maintenance doses, skip injections, and stop earlier than trial protocols require.

Applied to Retatrutide, a symmetric gap would push the real-world one-year average from the 28.7% TRIUMPH-4 number toward something closer to 21-23%. That is still a historically unprecedented outcome and still substantially above tirzepatide, but it is important for the category narrative because the marketing claim and the patient experience will diverge. The "Last 20%" thesis of this report is that the marginal clinical territory between the first 15% of weight loss (where semaglutide operates) and the next 10-15% (where Retatrutide and the triple class operate) is precisely the zone where real-world adherence, tolerability, and dose-titration patterns determine how much of the trial number actually reaches patients.

5.2 Discontinuation Is the Binding Constraint

Roughly 20% of patients discontinue GLP-1 therapy early and another 32% discontinue later in their treatment course, meaning more than half of patients who start semaglutide or tirzepatide are no longer on drug a year later. The dominant reasons, documented across multiple 2025 real-world studies, are: cost and insurance denials (47.6% of discontinuations), intolerance of GI side effects (14.6%), and supply shortages (11.8%). Weight outcomes track that discontinuation curve exactly: patients who never discontinue lose roughly 11.9% body weight at one year in the real world; patients who discontinue late lose 6.8%; patients who discontinue early lose 3.6%. The trial number is conditional on persistence. Persistence is not free.

Retatrutide inherits every structural driver of discontinuation that semaglutide and tirzepatide have, and it adds one of its own: the dose-dependent dysesthesia signal at 9 mg and 12 mg in TRIUMPH-4, reported at roughly 20.9% at the 12 mg dose. That is a novel safety finding in the incretin class, and it will influence both the FDA label and physician prescribing patterns. If the label includes a titration caution or if community physicians default to the 4 mg or 8 mg maintenance dose out of caution, the population-average weight loss Retatrutide actually produces could compress meaningfully below the 28.7% headline. Conversely, if the label is permissive and tolerability-mediated dose reductions are modest in practice, Retatrutide's real-world ceiling remains comfortably in the 22-25% range - above tirzepatide but below TRIUMPH-4's number.

5.3 Cost and Access Are Not Mechanism Problems

The most common reason patients discontinue GLP-1 therapy is cost. That is not a pharmacology problem and it is not a tolerability problem. It is a reimbursement problem, and it is the binding commercial constraint on this entire category. In 2024 and 2025, the obesity pharmacotherapy discussion inside payers and PBMs was dominated not by whether these drugs work but by whether the system can afford to cover them at population scale. List prices in the U.S. for semaglutide 2.4 mg and tirzepatide 15 mg sit in the $1,300-$1,500 per month range before rebates. A Retatrutide price that matches tirzepatide on a per-month basis, deployed across the 40% of U.S. adults who meet BMI criteria, implies a pharmacy budget impact no insurance system has yet priced.

The real-world implication is that Retatrutide's commercial uptake will be gated not by its clinical profile but by the rate at which payers expand obesity coverage and the degree to which Lilly can negotiate step-therapy arrangements that place Retatrutide at the top of the obesity formulary. Every other triple agonist in the pipeline - UBT-251, HM-15275, ASC37, and the Chinese programs - is a potential fast-follower that can compete on price and access rather than on efficacy-above-Retatrutide. The commercial game for positions 2 through 5 in the triple-agonist category is not "match Retatrutide's 28.7%." It is "deliver 20-24% at a materially lower price, with a better tolerability profile, or via an oral formulation that improves compliance."

5.4 The Dysesthesia Signal and What It Implies Mechanistically

Retatrutide's TRIUMPH-4 readout reported dysesthesia - abnormal sensory nerve sensations including tingling, burning, or reduced sensation - at 8% on the 9 mg arm and 20.9% on the 12 mg arm. The signal is absent or minimal at lower doses. It is a new finding in the incretin class; semaglutide, tirzepatide, and the dual GLP-1/GCGR agonists (survodutide, mazdutide, cotadutide) have not reported a comparable signal at their respective top doses.

Mechanistically, glucagon has documented effects on peripheral nervous system function, and the dose-dependence of Retatrutide's dysesthesia aligns with its GCGR potency. A reasonable working hypothesis is that the signal is GCGR-agonism-mediated and will appear, in milder form, across other triple agonists with equivalent GCGR potency. If that hypothesis holds, two things follow. First, the next-generation triples - HM-15275, UBT-251, ASC37 - will face the same signal at their respective efficacy-equivalent doses and will either label it, dose-escalate around it, or ratio-adjust their GCGR potency downward and accept lower weight-loss efficacy. Second, the dual GLP-1/GIP tirzepatide franchise is insulated from this particular signal, which is a material durability argument for tirzepatide's position even after Retatrutide launches.

5.5 Summary: Where the 28.7% Actually Goes

Our best synthesis of the four dynamics above is this: TRIUMPH-4's 28.7% number is a ceiling, not a floor, for what Retatrutide delivers at population scale. Real-world gap (-5 to -7 percentage points), dose-caution from the dysesthesia label (-2 to -4 percentage points), and cost-driven discontinuation (-3 to -5 percentage points of the persistence-adjusted average) together bring the realistic population-mean one-year weight loss on Retatrutide to roughly 17-22%. That is still historically dominant - it is comparable to tirzepatide's trial number - but it is considerably below the headline.

The Last 20% thesis is that the competitive dynamics over the next five years play out in exactly this gap. The winners will be the assets that close it: either via oral formulations that improve adherence (ASC37, SP-2297, Rani), via long-interval dosing that reduces attrition (monthly ASC37 SC, Fc-fusion MWN-101/ZX2021), via better tolerability ratios (small-molecule HM-15275), or via combination formulations that add amylin or calcitonin effects on top of the triple agonist (AstraZeneca's combination-centric patent position is the early signal of this thesis).

5.6 Who Loses If Triples Win

The triple agonist thesis is not free for the rest of the obesity field. If Retatrutide's 28.7% reads out across TRIUMPH-1/2/3 in the 22-28% range, three sets of assets face a sharp commercial re-pricing on the day of the first NDA approval. The dual GLP-1/glucagon franchise is the most exposed. Survodutide (Boehringer Ingelheim, Phase 3 SYNCHRONIZE) and mazdutide (Innovent, approved in China, filed ex-China) both sit in the ~14-18% placebo-adjusted range at their highest-dose arms - comfortably above semaglutide, comfortably below the triples. Both launch into a category where the efficacy ceiling has moved above them. Roche's CT-388 (dual GLP-1/GIP, acquired via Carmot) is structurally in the same position tirzepatide will occupy once Retatrutide reaches market: a credible, better-tolerated, second-tier asset competing on price and formulary access rather than on efficacy. And the second-wave Chinese duals (HRS9531, IBI362 follow-ons) face the same ceiling. The Section 8 IP map reads differently once this dynamic is priced in: the players whose patent estates are anchored to duals rather than triples are holding an asset class that just had its efficacy narrative compressed by six to eight percentage points.

6.0 Deals, Money, and Who Owns What

The deal map in the triple-agonist category is concentrated among four transactions, each of which reveals strategic intent about which format and which geography a sponsor is betting on.

6.1 Novo Nordisk + The United Laboratories (March 2025, up to $2.0B)

Novo Nordisk's license of UBT-251 closed March 24, 2025. Deal structure: $200 million upfront, up to $1.8 billion in development and sales milestones, for a maximum total of $2.0 billion. Novo acquired exclusive rights to develop, manufacture, and commercialize UBT-251 outside of mainland China, Hong Kong, Macau, and Taiwan; United Laboratories retained Chinese rights. The initial disclosed Phase 1b data supporting the deal showed 15.1% weight loss at 12 weeks at the highest dose group against a placebo that gained 1.5% - a ~16.6 percentage-point placebo-adjusted delta in three months, which was the specific signal that triggered the transaction.

Strategically, this deal is Novo's most aggressive explicit commitment to the triple-agonist modality to date. Novo did not have an internal triple agonist in the clinic at the time of the deal and required an external asset to avoid ceding the full triple-agonist category to Lilly's Retatrutide lead. The March 2025 timing - ten months after Lilly's Phase 2 Retatrutide readout in NEJM, two years ahead of Lilly's expected NDA - positions Novo to run UBT-251 global Phase 1b/2a in parallel with the Retatrutide Phase 3 program and to reach global Phase 3 a window behind Retatrutide but meaningfully ahead of any other triple agonist. The subsequent 19.7% Phase 2 readout at 24 weeks in China (February 2026) validated the commercial thesis behind the deal.

6.2 Novo Nordisk + Septerna (May 2025, up to $2.2B)

Novo's second major triple-agonist transaction was a broader small-molecule GPCR collaboration with Septerna announced May 2025: up to $2.2 billion total deal value, $200 million+ upfront, covering four oral small-molecule GPCR programs. One of the four is a GLP-1R / GIPR / GCGR triple agonist (SP-2297, preclinical). The other three are unannounced GPCR targets. This transaction is Novo's bet on the oral small-molecule vector - the same vector Lilly is pursuing with orforglipron (a GLP-1 oral small molecule now in Phase 3) and with its own preclinical oral follow-ons, and the vector that Ascletis (ASC37 oral tablet, a peptide rather than a small molecule, but pursuing the same compliance thesis) is targeting from a different molecular direction.

6.3 Jiangsu Hengrui + Kailera Therapeutics

Kailera Therapeutics was formed in 2024 as a U.S.-domiciled spin-out around a portfolio of incretin assets licensed from Jiangsu Hengrui, China's largest indigenous pharmaceutical company. Kailera IPO'd in 2025 with HRS9531 (dual GLP-1/GIP, Phase 3 China readout ~17.7% weight loss February 2026) as its lead asset and HRS-4729 (the triple agonist) as an earlier-stage follow-on. Financial terms of the Hengrui-Kailera transaction are not fully public; the structure appears to be an equity-plus-royalty arrangement with Hengrui retaining a significant ownership position in Kailera. Strategically, Hengrui-Kailera is the template for the China-to-U.S. licensing pattern that has become the dominant path for Chinese incretin assets to reach global markets - and given the depth of the Chinese preclinical long tail documented in Section 3.5, it is likely the template for multiple additional deals in 2026-2027.

6.4 D&D Pharmatech + Metsera + Pfizer

D&D Pharmatech, a Korean biotechnology company, licensed its DD-03 and DD-15 preclinical triple-agonist assets to Metsera, a U.S. obesity-focused biotech. Pfizer acquired Metsera in 2025, which consolidated DD-03 and DD-15 into Pfizer's internal pipeline. Financial terms of the Pfizer-Metsera transaction were disclosed; the D&D-Metsera upstream terms were not. This chain of transactions is Pfizer's principal visible triple-agonist exposure as of April 2026 - and because DD-03 and DD-15 remain preclinical, Pfizer's position lags Lilly's by approximately five years and Novo's by approximately three. Pfizer's obesity franchise is broader than its triple-agonist position (the company also has oral GLP-1 candidates in development), but its specific seat at the high-efficacy triple-agonist table is narrower than its global commercial scale would imply.

6.5 The Strategic Map

Summarized across the four transactions, the triple-agonist deal map splits along two axes: modality (peptide injection versus oral small molecule versus oral peptide) and geography (in-house U.S./EU discovery versus Chinese licensing versus Korean licensing). Lilly is the outlier on in-house peptide injection. Novo is the outlier on breadth - it is betting on all three modalities through four parallel programs. Pfizer and the smaller U.S. biotechs (Metsera, now-Pfizer; Kailera; Cascade) are pursuing either licensed-in Asian assets or internal preclinical discovery. The absence from this map worth noting is Roche, whose publicly disclosed obesity strategy is concentrated on dual GLP-1/GIP (CT-388) and does not include a triple-agonist deal or disclosed internal program.

Table 6.A - Major Triple-Agonist Transactions (2024-2026)

7.0 Efficacy Comparison: How Triples Beat Duals

The efficacy story is the core of the investment thesis. The question is not whether any of these drugs work - every Phase 2 and Phase 3 readout so far has crossed the clinical threshold for approval - but how they rank on the specific outcomes that matter commercially.

7.1 Placebo-Adjusted Mean Weight Loss - Head-to-Head

The table below consolidates the highest-dose arm for every clinical-stage incretin that has a public weight-loss readout, ordered by placebo-adjusted mean percent weight loss in the primary obesity trial. All numbers are from the sponsor's registrational or key Phase 2/3 readout in people with obesity without type 2 diabetes, with the trial durations noted.

Table 7.A - Highest-Dose Arm Weight-Loss Outcomes

Data sources: Phase 2/3 topline disclosures; real-world values differ - see Section 5.1. UBT-251 Novo global Phase 2 readout not yet available. Survodutide placebo-adjusted weight loss from SYNCHRONIZE-1/2 Phase 3 not yet publicly disclosed at full completion as of April 2026.

7.2 The Stairstep Pattern

Three observations from the table are structurally important to the investment thesis.

First, the class hierarchy is cleanly stairstepped. Pure GLP-1 (semaglutide 2.4 mg) delivers ~15%. Dual GLP-1/GIP (tirzepatide 15 mg) delivers ~21%. Triple GLP-1/GIP/GCGR (Retatrutide 12 mg) delivers ~24-29% depending on trial. Each mechanism addition adds roughly 5-7 percentage points. That linearity is a feature, not an accident - it is the basis for the Section 2 thesis that glucagon is the third lever and that the class has a real mechanistic ceiling above the dual.

Second, the dual GLP-1/GCGR class (mazdutide, survodutide) performs comparably to semaglutide, not to tirzepatide. Mazdutide 6 mg at 48 weeks is ~14%; mazdutide 9 mg at 48 weeks is ~18%. These are respectable but not class-defining numbers. The addition of GCGR to GLP-1 is additive but not as powerful as the addition of GIP to GLP-1 - a counterintuitive result given the strength of Retatrutide's glucagon-driven signal, and one that underscores how much of the triple-agonist story is about the combination of the three receptors rather than the magnitude of any single one.

Third, UBT-251's 19.7% at 24 weeks is the tempo outlier of the class. At roughly half the duration of Retatrutide's Phase 2 (24 weeks versus 48 weeks), UBT-251 has produced weight-loss numbers approaching the 8-mg Retatrutide arm. If UBT-251's trajectory is linear through 48 weeks, the drug could approach or match Retatrutide's 24.2% Phase 2 number. The global Novo Phase 1b/2a readout in 2027 is the critical test of that extrapolation.

7.3 Responder-Rate Distributions

Means are the headline but distributions are the commercial reality. A drug with 28% mean weight loss can have very different commercial and clinical profiles depending on whether that mean is produced by a narrow cluster of super-responders or by broad consistent response across the enrolled population. The Phase 2 Retatrutide data allows explicit decomposition of responder distributions at multiple thresholds.

Table 7.B - Retatrutide Phase 2 Responder Rates (12 mg arm, 48 weeks)

Source: Phase 2 obesity trial (NCT04881760), 12 mg arm. TRIUMPH-4 distribution at 68 weeks would be expected to shift right of this table given higher observed mean.

The distribution is not narrow. Roughly 46% of Retatrutide 12 mg patients reached at least 25% weight loss at 48 weeks - a threshold that sits squarely inside the clinical outcome range historically associated with sleeve gastrectomy and Roux-en-Y gastric bypass. Roughly 26% reached at least 30%, which overlaps with the high end of bariatric outcomes. For the first time in the history of obesity pharmacotherapy, a material fraction of patients on a single drug reach the outcomes previously accessible only through surgery.

7.4 Bariatric Surgery - The Outcome Benchmark

Roux-en-Y gastric bypass produces mean percent total body weight loss of approximately 25-30% at one year, declining modestly to approximately 22-25% at five years with a wide distribution - 20.4% of RYGB patients fail to reach even 20% total body weight loss at five years in the SleeveBypass randomized trial. Sleeve gastrectomy produces approximately 20-25% at one year, declining to 18-22% at five years, with 35.1% of patients failing to reach 20% at five years.

Retatrutide's TRIUMPH-4 68-week number (28.7%) is at the upper end of RYGB's one-year outcome range and above the five-year range for both procedures. Even Retatrutide's Phase 2 12-mg arm at 48 weeks (24.2%) is comparable to sleeve gastrectomy's one-year mean. This is the headline story of the category and the specific basis for the Section 1 claim that pharmacotherapy has crossed the threshold from "serious medicine" to "surgical substitute."

The important caveat is that surgery produces durable weight loss with a single intervention; Retatrutide requires continuous chronic administration. Real-world persistence with GLP-1 medications is poor (Section 5.2), and discontinued patients regain weight over time at rates that vary by study. Surgery's "all-in" cost at 10-year horizon remains lower than Retatrutide at commercial pricing over the same horizon. For patients, payers, and health systems, the triple-agonist era does not eliminate bariatric surgery - it creates a new category of patients who can access surgical-equivalent weight loss without surgical risk, provided they remain on drug and access it at a price their payer will cover.

7.5 Secondary Outcomes - Glycemia, Blood Pressure, Tolerability

HbA1c (T2D and obesity+T2D populations). Retatrutide 12 mg reduces HbA1c by approximately 2.0 percentage points; UBT-251 6 mg reduces HbA1c by 2.16 percentage points in its T2D Phase 2 (March 2026 readout); tirzepatide 15 mg reduces HbA1c by 2.0-2.5 percentage points across SURPASS trials; semaglutide 2.4 mg reduces HbA1c by 1.4-1.6 percentage points. The triple agonists are on par with tirzepatide and meaningfully above semaglutide on glycemic effect, consistent with GIPR's contribution to insulin sensitization.

Systolic blood pressure. Retatrutide produces 7-10 mmHg reductions at top doses at 48-68 weeks; tirzepatide produces 6-8 mmHg at 15 mg; semaglutide produces 4-6 mmHg at 2.4 mg. The magnitudes are weight-loss-proportional and broadly consistent across the class.

GI tolerability and discontinuation. Retatrutide 12 mg Phase 2 nausea rates ran approximately 25-30%, with treatment-emergent discontinuation approximately 13-15% at the top dose. Tirzepatide 15 mg discontinuation runs 6-8% in trials. Semaglutide 2.4 mg discontinuation runs 4-6%. The triple agonists carry a meaningfully higher tolerability cost than GLP-1 or dual GLP-1/GIP at equivalent efficacy doses - consistent with the GCGR contribution to both efficacy and GI signal.

Cardiovascular and renal outcomes. TRIUMPH-3 (CVOT) and TRIUMPH-CV/renal are both running and will not read out until late 2026 or 2027. Survodutide's SYNCHRONIZE-CVOT (n=1844 per arm) is running in parallel. The cardiovascular outcome question is the single largest open-source efficacy question in the category and the one most likely to either compress or expand the clinical differentiation between triples, duals, and pure GLP-1 in 2027-2028.

8.0 IP Strategy by Player

The patent landscape around GCGR/GIPR/GLP-1R tri-agonism is not usefully described by counts. What matters is who is in the space, what they are building, and what their estates actually cover. Organized by the player-level story, the picture looks like this.

How to read a patent estate, in plain English. A drug program is protected by stacked layers of patents, not one. The composition-of-matter layer protects the molecule itself. The method-of-use layer protects using that molecule to treat a specific disease, which matters because a competitor could invent a different molecule and still hit the same wall. The formulation layer protects how the molecule is mixed and stabilized into a product that can survive shipping and storage. The delivery layer protects the injection device, the oral tablet chemistry, or the ingestible capsule. The manufacturing layer protects how the molecule is made at scale.

A strong estate covers all five. A weak one covers only the molecule and lets generics design around the rest. A patent thicket is what you get when a single player stacks dozens of overlapping filings across all five layers to create a dense enough wall that no fast-follower can legally get through without a license. The table below is our read on what each major player is actually building.

8.0a The Five IP Archetypes in This Space

Every meaningful estate in the triple-agonist field falls into one of five patterns. Knowing which pattern a player is running tells you more about their strategic intent than any individual filing does.

1. The Clinical Fortress. Composition-of-matter on the molecule, backed up by formulation, delivery, and manufacturing layers that specifically match that molecule's commercial form. Anchored on an asset you can name. Examples here: Hanmi (HM-15275), Lilly (Retatrutide), D&D Pharmatech (DD-03 / DD-15).
2. The Latent Royalty Position. Heavy method-of-use filings, light or absent composition-of-matter, no disclosed clinical asset. The strategy is not to sell a drug. It is to collect a royalty on every drug that treats the indication. Example here: Sanofi.
3. The Foundational Scaffold. Design-principle filings on peptide architectures, receptor-ratio tuning approaches, and half-life extension chemistry that predate the current asset generation. Not a commercial position on its own; becomes a licensing stream. Example here: Indiana University.
4. The Optionality Portfolio. A moderately-sized estate across explicit triple claims and method-of-use, with no committed clinical asset yet. Designed to preserve flexibility to advance internally or license out. Examples here: Zealand, Roche, AstraZeneca (combination-angled variant).
5. The Asset-by-Asset Build. Molecule-level filings tied to individual clinical candidates, with less investment in thicket layers. Common pattern across Chinese sponsors (Innovent, Hengrui, Zhejiang Doer, Jiangsu Zhongxin, and the academic-linked programs). The expectation is that ex-China licensing partners will build the thicket around the molecule after license.

The assignees below are organized by which archetype they are running, then by what that tells you about their likely next moves.

8.1 Hanmi Pharmaceutical - Estate Matched to Clinical Asset

Hanmi's IP estate is the most clinically anchored in the field. Across 107 publications and 17 patent families, Hanmi's claims concentrate on explicit triple-agonist composition-of-matter, half-life extension chemistry, and formulation - a profile that maps directly onto HM-15275 and its predecessor HM-15211. What Hanmi is building is a single-asset fortress: composition claims around the molecule itself, formulation and stability claims around the drug product, and half-life extension chemistry claims covering the long-acting design. The estate is narrow in scope (concentrated on its own molecules) but deep in each direction that matters for that molecule. Hanmi is the only top-IP holder in the field with a clinical-stage triple agonist in its own pipeline, and the estate reflects that alignment.

8.2 Sanofi - The Largest Latent Position

Sanofi holds 114 publications across 14 patent families relevant to the space, more than any other single assignee in the data. What makes Sanofi's position unusual is that it is heavily weighted toward method-of-use claims with very little composition-of-matter, formulation, or delivery activity. Sanofi has no disclosed triple agonist in its public pipeline. A plausible reading of this pattern is that Sanofi's estate functions as a strategic option - either the company is preparing an internal program whose molecule has not yet been disclosed, or the method-of-use filings are being positioned to generate royalty claims against competitor products as they reach market. Either interpretation makes Sanofi the largest asymmetric IP position in the field and the most likely source of unexpected IP friction over the next five years.

8.3 Eli Lilly - Narrow, Deep, Clinical-Asset-Anchored

Lilly's estate (25 publications, 6 families) is much smaller in publication count than Sanofi's or Hanmi's, but its composition is concentrated on what matters for Retatrutide: explicit triple-agonist composition-of-matter claims, half-life extension chemistry (the fatty-acyl side chain architecture), formulation, and - notably - two publications in the oral delivery bucket. The oral delivery filings are the most interesting forward-looking signal in Lilly's estate: Lilly has already demonstrated with oral semaglutide (via the Novo-Lilly prior-art relationship) and orforglipron (its own oral small-molecule GLP-1) that the company takes the oral incretin vector seriously. Two oral-bucketed filings on the triple-agonist scaffold suggest an early-stage program to put an oral-deliverable version of the Retatrutide lineage forward. The clinical asset (Retatrutide) sits at the center of this estate, and the estate is designed to defend that asset through launch and into the decade of follow-on products.

8.4 Indiana University - The Foundational Estate

Indiana University's estate (39 publications, 7 families) sits beneath Lilly's and beneath much of the dual-agonist field as foundational peptide-design prior art. Richard DiMarchi's group at Indiana generated the academic chemistry that anchors oxyntomodulin-derived co-agonists, the design principles behind GLP-1/glucagon duals, and the peptide-scaffolding approaches that Lilly, Zealand, Boehringer Ingelheim, and others have licensed or built upon. What Indiana's estate covers is the design-principle layer: peptide-sequence families, receptor-ratio tuning approaches, and half-life extension architectures. The estate is not itself a commercial position, but its licensees constitute a significant share of the clinical pipeline.

8.5 Zealand Pharma - Dual-Agonist Mature, Triple-Agonist Early

Zealand's estate (17 publications, 4 families) is heavily concentrated on explicit triple-agonist and method-of-use claims. Zealand's commercial heritage is in the GLP-1/glucagon dual space - dapiglutide, elsiglutide, and several partnered duals - and the triple-agonist filings represent the company's natural technical extension into the three-receptor pathway. Zealand does not currently have a disclosed clinical-stage triple agonist, which means its IP position is ahead of its product position. Any triple-agonist program Zealand announces in 2026-2027 will be built on top of this estate.

8.6 AstraZeneca - Combination-Centric

AstraZeneca's 17 publications across 5 patent families have a striking single-bucket concentration: every publication falls in the COMBO bucket (triple agonist in combination with another metabolic agent). AstraZeneca's commercial obesity heritage is cotadutide (GLP-1/glucagon dual, divested) and its longer-term diabetes franchise (dapagliflozin and its combinations). The triple-agonist combination filings suggest AstraZeneca is positioning either for a combination-product strategy (a triple agonist co-formulated or co-packaged with an SGLT2 inhibitor, an amylin analog, or a calcitonin/amylin dual like cagrilintide) or for a licensing-target role where the combination claims would apply to partner products. What AstraZeneca is building is not a molecule; it is a combination-of-assets thesis.

8.7 Roche / Genentech - Method-of-Use Heavy

Roche's estate (16 publications, 2 families) is concentrated on method-of-use with a single device filing. Roche's public obesity strategy, as of April 2026, centers on CT-388 (a GLP-1/GIP dual acquired through the Carmot Therapeutics acquisition) and a deep orforglipron-competitor oral GLP-1 program. The triple-agonist filings are narrower than Hanmi's or Lilly's, consistent with the company's public positioning as a GLP-1/GIP dual specialist with an optionality position on triples rather than a lead commitment.

8.8 D&D Pharmatech - Half-Life-Extension Focused

D&D Pharmatech's 8 publications across a single patent family sit at the intersection of explicit triple-agonist composition and half-life extension chemistry. The concentrated filing activity in a single family suggests a tight platform position around a specific molecular architecture - consistent with DD-03 and DD-15 (both licensed to Metsera and now in Pfizer's portfolio) as the two principal commercial outputs of that platform.

8.9 Chinese Sponsors - Distributed, Early, Asset-Anchored

The Chinese IP footprint in the space is distributed across Innovent, Hengrui, Zhejiang Doer, Jiangsu Hengrui, Haisco Pharmaceuticals, Shenzhen HEC, Shenzhen Bay Laboratory, and a growing number of academic-linked filings. No single Chinese sponsor dominates the way Hanmi or Sanofi do. What the Chinese estates broadly cover is molecule-level composition claims tied to individual pipeline assets (UBT-251, IBI-3012, HRS-4729, MWN-101/109, ZX2021, ASC37), with less activity in the method-of-use and combination spaces. The pattern is consistent with asset-by-asset IP development rather than platform-level thicketing - Chinese sponsors are protecting individual molecules with the expectation of ex-China licensing as those molecules mature.

8.10 Novo Nordisk - Underweight on Filings, Overweight on Deals

Novo's direct filings against the triple-agonist keyword set are modest - 2 publications across 2 families. What Novo is building in the IP layer is distinct from what the top filers are building: rather than generating organic composition claims, Novo is assembling an estate through licensing (UBT-251 from United Laboratories, small-molecule rights through Septerna) and through the internal NNC-06620419 program whose filings are likely still confidential or have not yet surfaced in the data window. The broader Novo obesity estate is concentrated on semaglutide, cagrilintide, amycretin, and the dual-platform portfolio; the triple-agonist position is the most recent and least filing-anchored of those layers.

9.0 Open Questions and What We're Watching

Five things will determine how this pathway plays out over the next eighteen months.

First, Retatrutide TRIUMPH-1/2/3. The 28.7% at 68 weeks in TRIUMPH-4 is observed in a specific population (obesity + knee OA). The remaining TRIUMPH readouts, particularly TRIUMPH-1 in general obesity and TRIUMPH-3 in obesity + cardiovascular risk, will establish whether the 28% threshold holds across less-selected populations or whether it relaxes toward the 20-24% range Phase 2 established.

Second, the dysesthesia signal. The 9 mg and 12 mg dose-dependent dysesthesia finding in TRIUMPH-4 is a novel safety signal in the incretin class. How the FDA labels the signal - whether as a boxed warning, a dose-titration requirement, or a monitoring recommendation - will shape the commercial dose-use pattern and therefore the real-world average weight loss at population scale.

Third, UBT-251 global bridge. Novo's global Phase 1b/2a readout in 2027 is the test of whether the 19.7% at 24 weeks observed in the Chinese Phase 2 generalizes. If UBT-251 global reads out above 20%, Novo has a credible fast-follower to Retatrutide.

Fourth, Hanmi HM-15275 Phase 2. Small-molecule Class B GPCR agonism is hard. If Hanmi's Phase 2 confirms the Phase 1 weight-loss trajectory on a long-acting dosing cadence, the asset becomes the most commercially differentiated triple agonist after Retatrutide. If it doesn't, the broader small-molecule-oral thesis (SP-2297, CS-120070, RAY-0221) loses its clinical proof point.

Fifth, Ascletis ASC37 IND and Phase 1 oral bioavailability. If the oral tablet form of ASC37 shows sufficient human PK in Phase 1 H2 2026, the category changes. If the oral form fails and only the once-monthly SC form advances, ASC37 becomes one more long-acting injectable in a crowded pipeline.

10.0 The IP Layer Decoded: What the Filings Actually Tell You

The drugs are the headline. The intellectual property is the moat. A retatrutide-level efficacy readout is reproducible in principle; a well-constructed patent estate is not. What follows is the strategic decode of the landscape documented in Section 8, translated into what it means for the four audiences most likely to be reading this report.

10.1 If You Are a Sponsor With an Active Triple-Agonist Program

Three questions matter more than any other. First, is your composition-of-matter claim narrow enough to survive a post-grant opposition from a large-pharma competitor with an overlapping estate, and broad enough to cover the follow-on molecules you are likely to generate over the next ten years? Narrow-and-specific is the right answer; broad-genus claims in this space are already being chipped away at the patent offices. Second, does your estate extend to the clinical form of your drug, not just the molecule? The majority of lost market share in prior incretin programs has been around formulation, delivery device, and dosing regimen, not molecule identity. If your formulation layer is thin, that is where the fast-follower will enter. Third, have you filed continuation and divisional applications on the method-of-use claims for the indications you are not actively pursuing clinically? Retatrutide will reach market for obesity and obesity-plus-comorbidity. The sleep apnea, MASH, cardiovascular-risk, and chronic kidney disease indications are all separate patent opportunities, and the method-of-use filings on those indications will be worth more in five years than the composition claims will.

10.2 If You Are Evaluating a Molecule to License In

The composition claim tells you what molecule you are buying. That is necessary but insufficient. The questions a serious diligence pass has to answer are whether the estate covers the formulation you intend to commercialize, whether it blocks the most likely generic design-arounds, whether freedom-to-operate is clear against Sanofi's method-of-use filings and against Indiana University's foundational scaffold estate, and whether the estate is structured to support the pediatric and geographic expansion strategies that drive the back half of the asset's lifecycle value. A license that looks clean in the U.S. can be three-layers-deep encumbered in the E.U. by supplementary protection certificates that were never flagged in the data room. We see this pattern repeatedly in Chinese-to-U.S. licensing deals where the ex-China estate was not built with the same discipline as the China estate.

10.3 If You Are Building a Fast-Follower or a Biosimilar

The design-around question in this space is harder than in prior incretin generations because the receptor-ratio tuning is the commercial differentiator, and narrow molecular claims on specific ratios are the densest concentration of filings. A biosimilar to Retatrutide is not a trivial product development exercise; a molecular fast-follower that hits different receptor ratios and clears the method-of-use filings will need to have composition claims of its own and a freedom-to-operate position across Lilly, Hanmi, Sanofi, Indiana, and Zealand. The cheapest path into the category is through the combination-product vector AstraZeneca is signaling - triple agonist plus amylin, plus calcitonin, plus an SGLT2 inhibitor - because that path is currently underclaimed and because the combination use-pattern generates its own defensible IP layer.

10.4 If You Are an Investor Evaluating the Category

The single most useful thing we can tell you about this space is that the market-cap-weighted patent position does not track the market-cap-weighted pipeline position. Lilly trades as the obvious winner because Retatrutide is the only Phase 3 asset. That narrative is correct for the 2026-to-2029 commercial window. It is not correct for the 2030-and-beyond window, in which Sanofi's latent position, Hanmi's clinical-fortress build, Indiana's foundational scaffold, and the Chinese asset-by-asset pipeline all become priced-in variables. The players who are underweight in patents relative to their disclosed pipeline are the ones most likely to be outside-licensing in the next twenty-four months; the players overweight on filings with no disclosed asset are the ones most likely to either announce a surprise clinical program or trade into a pure-licensing business model. Both represent repricing events that are not currently in consensus.

10.5 The Five Patent-Layer Bets Worth Watching

Oral delivery formulation filings. ASC37 and SP-2297 will generate a new formulation-layer IP cluster over the next eighteen months. Lilly's two oral-delivery filings on the retatrutide scaffold are the earliest signal that the Phase 3 incumbent is preparing for this transition.

Combination-product filings. AstraZeneca's COMBO-only estate is the most explicit bet, but Novo's cagrilintide plus incretin filings and any triple-plus-amylin filings that emerge will be the layer that wins or loses the 2030 formulary negotiation.

Tissue-selective delivery claims. Innovent's IBI-3012 ADC program opens a modality nobody else is positioned for. The first five filings on liver-selective or adipose-selective triple agonism will be disproportionately valuable.

Long-acting device and implant filings. The monthly and longer-interval dosing story is commercially large and currently underclaimed. Implantable pump delivery, long-acting depot formulations, and device-linked dosing regimens will generate the next IP gold rush in this space.

Post-approval method-of-use expansion. Every TRIUMPH readout that confirms retatrutide for a new indication (OSA, MASH, CKD, heart failure with preserved ejection fraction) is a distinct method-of-use filing opportunity. The sponsors who build those layered claims systematically will collect the long tail of this asset's value.

11.0 The Bottom Line

The science is settled. Retatrutide's 28.7% at 68 weeks closes a two-decade arc that began with every major pharma trying to shut the glucagon receptor off. Glucagon, co-agonized with GLP-1 and GIP, is the lever that pushes obesity pharmacotherapy into surgical-outcome range. TRIUMPH-1 through TRIUMPH-3 will sharpen the number. They will not change the thesis.

The commerce is not. Real-world attrition, cost-driven discontinuation, and the dose-dependent dysesthesia signal together bring the population-mean weight loss on Retatrutide to roughly 17-22%. Historically dominant, materially below the headline. That gap - between what the trial showed and what patients actually receive - is the Last 20%. Every fast-follower strategy in the pipeline is, in one form or another, a play to close a piece of it. The position-two winner will be the asset that delivers 20% at a price payers cover, a dose patients tolerate, and a compliance burden they accept.

The IP is what survives. The molecules will eventually be genericized. The receptor-ratio tuning, the formulation and delivery layers, the method-of-use filings on indications that have not yet read out, and the combination claims that cross triples into amylin, calcitonin, and SGLT2 are the positions that will still be generating revenue in 2040. Sanofi's latent estate, Hanmi's clinical fortress, Indiana University's foundational scaffold, the Chinese asset-by-asset build, and the combination-centric bets AstraZeneca and Novo are assembling all map to the decade-plus value-capture window that sits behind the approval milestones.

Twenty-seven programs are racing into a category where the mechanism is known, the readouts are imminent, and the market is larger than any drug class that has ever come before. The winners will not be the sponsors who reach the market first. They will be the sponsors who reach the market with the IP stack strong enough to hold it.

The story of the GLP-1 era was whether the drugs work. The story of the triple-agonist era is who owns them.